Please login or register first to view this content.
Endocrine Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
Oral Semaglutide NDAs Seeking T2D Indication, CV Risk Reduction
Dapagliflozin Reduces MACE, CV Death in Patients With T2D and Prior MI
Clinical Outcomes Compared With Generics, Brand-Name Drugs for Chronic Conditions
Raspberries May Aid Glucose Control With Prediabetes
Adding Semaglutide to SGLT-2 Inhibitor Tx Improves Glycemic Control, Reduces Body Weight in T2D
Authorized Generic of Humalog Soon to Be Available at Reduced Price
Soliqua 100/33 Indication Expanded to Include T2D Patients Uncontrolled on Oral Antidiabetic Agents
Farxiga, Xigduo XR Labeling Updated to Include Use in T2D Patients With Moderate Renal Impairment
Liquid Levothyroxine Formulation Now Available to Treat Hypothyroidism
First Alternate Controller Enabled Insulin Pump FDA-Cleared
Linagliptin Non-Inferior to Glimepiride in Long-Term Cardiovascular Outcome Study
Small Increase in HbA1c Seen With Switch to Human Insulin in T2DM
Does DPP-4 Inhibitor Use Increase the Risk of Developing IBD?
Maternal Glucose in Pregnancy Tied to Child’s Glucose Outcomes
Short Duration Between Dinner, Bed Has No Effect on HbA1c
Insulin Price More Than Doubled in the United States
Oral Hepatoselective Glucokinase Activator Promising in T2DM
FDA Committee Votes on Oral T1D Treatment Sotagliflozin